Bio-Rad Laboratories (NYSE:BIO) Announces Earnings Results, Beats Expectations By $0.42 EPS

Bio-Rad Laboratories (NYSE:BIO) posted its earnings results on Wednesday. The medical research company reported $2.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.23 by $0.42, FiscalAI reports. The business had revenue of $656.40 million during the quarter, compared to analysts’ expectations of $649.94 million. Bio-Rad Laboratories had a return on equity of 3.54% and a net margin of 8.59%. Bio-Rad Laboratories’s revenue for the quarter was up .5% compared to the same quarter last year. During the same period in the prior year, the business earned $2.26 EPS.

Here are the key takeaways from Bio-Rad Laboratories’ conference call:

• Bio-Rad returned to modest currency-neutral growth in Q3, with revenue up 0.7%. Non-GAAP gross margin rose to 54.5% from 53.5% a year earlier, and non-GAAP diluted EPS increased to $2.65 from $2.26.
• ddPCR remained a growth driver: portfolio revenue rose 7% currency-neutral, while instrument revenue increased more than 20% for a third consecutive quarter. Management said placements and competitive wins support the opportunity, though consumable pull-through has not yet normalized and may remain soft into 2027.
• Bio-Rad reaffirmed 2026 currency-neutral revenue growth guidance of -3% to +0.5%, expecting results near the midpoint. It anticipates continued academic and government market weakness, a Q4 sequential decline in gross margin, and a sequential decline in process chromatography revenue.
• Management cited ongoing market pressures, including NIH outlays down about 15% year over year in Q3 and pricing pressure in China. It estimates China’s updated healthcare guidelines could reduce 2027 revenue by a mid-single-digit millions of dollars amount; elevated Middle East logistics costs may also persist into 2027.
• Management said it is focused on returning to positive revenue growth and expanding margins in 2027, while cautioning that the recovery may not be fully normalized. The restructuring program is expected to deliver $30 million–$35 million in savings, with full benefits beginning in 2028.

Bio-Rad Laboratories Stock Up 1.2%

BIO traded up $4.49 during trading hours on Wednesday, hitting $379.40. 281,797 shares of the company’s stock were exchanged, compared to its average volume of 224,917. The stock has a market cap of $10.15 billion, a price-to-earnings ratio of 40.40 and a beta of 1.06. Bio-Rad Laboratories has a 1-year low of $236.73 and a 1-year high of $396.23. The stock’s 50-day moving average is $374.53 and its two-hundred day moving average is $314.61. The company has a quick ratio of 2.33, a current ratio of 3.14 and a debt-to-equity ratio of 0.11.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on BIO shares. Zacks Research upgraded shares of Bio-Rad Laboratories from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 11th. Citigroup raised their price objective on shares of Bio-Rad Laboratories from $300.00 to $330.00 and gave the stock a “hold” rating in a report on Wednesday, August 5th. Weiss Ratings raised shares of Bio-Rad Laboratories from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, October 8th. Royal Bank Of Canada increased their target price on Bio-Rad Laboratories from $320.00 to $370.00 and gave the stock an “outperform” rating in a report on Wednesday, August 5th. Finally, Wells Fargo & Company increased their target price on Bio-Rad Laboratories from $310.00 to $330.00 and gave the stock an “equal weight” rating in a report on Wednesday, August 5th. One analyst has rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, Bio-Rad Laboratories currently has an average rating of “Hold” and an average target price of $343.33.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc develops, manufactures and markets products and systems used in life science research and clinical diagnostics. Its life science portfolio includes laboratory instruments, reagents, software and consumables used in areas such as genomics, proteomics, cell biology, biopharmaceutical development and quality control.

The company’s clinical diagnostics business provides systems, reagents and software for blood typing, infectious disease testing, diabetes monitoring, quality control and other diagnostic applications.